Anyone have an idea on timing of the preclinical for other neurodegenerative disorders?
AD driven by amyloid plaque and tau aggregation are reduced by mTor inhibition. Monepantel is a potent mTor inhibitor, not hard to put two and two together.
Wonder how the market will respond we would double the opportunity for PAA.
Anyone have an idea on timing of the preclinical for other...
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $111.9M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.3¢ | 23.0¢ | $55.17K | 239.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 158933 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 177811 | 6 |
View Market Depth
| Last trade - 12.02pm 17/10/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |